We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: Central/South America,Western Europe,Eastern Europe,Asia,Middle East,Africa
Monthly Production Capacity: large capacity
Contract Manufacturing: Workable
Packaging Information: According to customs' requirements
Delivery Lead Time: USP, BP, EP etc
Sample Provided: no
Payment Terms: depends, normally about 2 months
Product : Rosiglitazone Tartrate Dispersible Tablets
Specification : 4mg
Standard : In - house
Packing : 6’s/blister
Description :
Rosiglitazone Tartrate is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. Rosiglitazone Tartrate improves glycemic control while reducing circulating insulin levels.
Rosiglitazone Tartrate is not chemically or functionally related to the sulfonylureas, the biguanides, or the alpha-glucosidase inhibitors.
Each pentagonal film-coated tablet contains rosiglitazone Tartrate equivalent to rosiglitazone 4 mg for oral administration.
Indications and Usage :
1 Monotherapy and Combination Therapy
Rosiglitazone Tartrate Dispersible Tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
2 Important Limitations of Use
Due to its mechanism of action, Rosiglitazone Tartrate Dispersible Tablets is active only in the presence of endogenous insulin. Therefore, Rosiglitazone Tartrate Dispersible Tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
The coadministration of Rosiglitazone Tartrate Dispersible Tablets and insulin is not recommended.
The use of Rosiglitazone Tartrate Dispersible Tablets with nitrates is not recommended.
Three years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
